True North Therapeutics to Present Data on Lead Antibody Selectively Targeting the Classical Complement Pathway at the 55th American Society of Hematology Annual Meeting

Preclinical Data Demonstrate Potential to Treat Complement-mediated Rare Diseases by Inhibiting the Classical Complement Pathway

 

South San Francisco, CA – November 13, 2013 – True North Therapeutics, a biotechnology company developing novel therapies that selectively inhibit the Complement system for rare diseases, today announced that it has been selected to make an oral presentation of its lead antibody drug candidate and novel mechanism for targeting the Classical Complement pathway at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 7-10, 2013 in New Orleans, LA.

The presentation will describe preclinical studies and ex vivo efficacy results for True North’s first-in-class monoclonal antibody that selectively inhibits a target of the Classical Complement pathway for autoantibody-driven rare diseases.  An abstract summarizing the data is available on the ASH website and can be accessed using the link below.

Oral Presentation:

  • (Abstract # 42): Title: TNT009, a Classical Complement Pathway Specific Inhibitor, Prevents Complement Dependent Hemolysis Induced by Cold Agglutinin Disease Patient Autoantibodies
  • Presenter: Sandip Panicker
  • Sunday, December 8, 2013. 6:15 PM
  • Session: 401. Basic Science and Clinical Practice in Blood Transfusion: Alloimmunization–Causes, Consequences and Management (5:00 PM – 6:30 PM)
  • Room: Ernest N. Morial Convention Center, 275-277
  • https://ash.confex.com/ash/2013/webprogram/Paper64043.html

About True North Therapeutics

True North Therapeutics is a biotechnology company developing novel therapies that selectively target the Complement pathway of the immune system to address fundamental mechanisms in diseases with high unmet need, including rare diseases. The company’s lead monoclonal antibody drug candidate, TNT009, selectively inhibits a target in the Classical Complement pathway, thereby preventing downstream disease processes involving phagocytosis, inflammation, and cell lysis. True North’s drug development programs are focused on Complement-mediated diseases in the hematologic, renal, and neurological therapeutic areas. True North Therapeutics is located in South San Francisco, California. For more information, please visit www.truenorthrx.com.

Media Contact:
kathryn@theyatesnetwork.com
Tel: 845-635-9828
kathryn@theyatesnetwork.com